常规放疗结合后程立体定向放射治疗老年非小细胞肺癌患者的预后分析

张文学; 姜炜; 吕仲虹; 曹永珍

张文学 , 姜炜 , 吕仲虹 , 曹永珍

文章导航 > 国际放射医学核医学杂志 > 2007, 31 > 2: (125-127)

引用本文:

Citation:

常规放疗结合后程立体定向放射治疗老年非小细胞肺癌患者的预后分析

1. 300060 天津, 天津市环湖医院放疗科;
2. 300052 天津, 天津医科大学总医院放疗科
中图分类号: R730.55

Prognostics analysis of common radiotherapy combined stereotactic radiotherapy for non-small cell lung cancer of old patients

1. Department of Radiotherapy, Tianjin Huanhu Hospital, Tianjin 300060, China;
2. Department of Radiotherapy, General Hospital of Tianjin Medical University, Tianjin 300052, China
CLC number: R730.55

摘要: 目的观察老年非小细胞肺癌立体定向放疗疗效,并探讨其预后因子。方法 128例老年非小细胞肺癌患者行常规放疗结合立体定向放疗,定期随访。结果全组患者1年生存率65.72%,单因素分析表明肿瘤体积、肿瘤剂量、卡氏评分影响近期结果,多因素分析仅肿瘤体积和肿瘤剂量为近期疗效预后因子,与生存期有关的预后因素为近期疗效、肿瘤剂量、临床分期。结论立体定向放疗可延长生存时间,对Ⅲ期患者,肿瘤剂量提高至72Gy是安全的。
- 癌,非小细胞肺 /
- 立体定向放射治疗 /
- 老年人 /
- 预后
Abstract: Objective To observe the effect of stereotactic radiotherapy (SRT) for non-small cell lung cancer(NSCLC) of old patients. Method 128 NSCLC old patients receive common radiotherapy and SRT. The results was followed. Results 1-year survival rate is 65.72% for all patients on univariate analysis radiation dose,tumor volume, Karnofsky performance status (KPS) are significantly associated with first follow-up response(FFR). On multivariate analysis only the first two are significant. Prognostic factors of survival time are FFR, tumor dose and clinical stage. Conclusions SRT can significantly raise survival time expecially for phase Ⅲ patients. The dose 72 Gy for NSCLC old patients is safe.
- Cancer, non-small cell lung /
- Stereotactic radiotherapy /
- Aged /
- Prognostic factors
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Morita K, Fuwa N, Suzuki Y, et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I:retrospective analysis of 149 patients. Radiother Oncol, 1997, 42(1):31-36.
[2]	Etiz D, Marks LB, Zhou SM, et al. Influnce of tumor volume on survival in patients irradiation for non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2002, 53(4):835-846.
[3]	Nagata Y, Negom Y, Aoki T, et al. Clinical outcomes of 3-D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frame. Int J Radiat Oncol Biol Phys, 2002, 52(5):1041-1046.
[4]	Abratt RP. Modeling tumor and treated lung tumor volume influence in the irradiation of non-small cell lung cancer patients. Int J Radiat Oncol Biol Phys, 2001, 49(2):481-485.
[5]	Chung PC, Miackillop WJ, Dixon P, et al. Involved-field radiotherapy alone for early stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2000, 48(3):703-711.
[6]	Bradley, Graham MV, Winter K, et al. Toxicity and outcome results of RTOG 9311:a phase I-II dose-esclation study using three-dimentional conformal radiotherapy in patients with inoperable non-smallcell lung carcinoma. Int J Radiat Oncol Biol Phys, 2005, 61(2):318-328.
[7]	Wu KL, Jiang GL, Liao Y, et al. Three-dimensional conformal radiation therapy for non-small cell lung cancer:A phase Ⅰ/Ⅱ dose escalation clinical trial. Int J Radiat Oncol Biol Phys, 2003, 57(5):1336-1344.
[8]	Schwegler N, Vrh N, Kern T, et al. Local efficiency of percutaneous radiotherapy in lung cancer. Analysis of 215 repeated bronchoscopies in relation to applied radiation dosage. Strahlenther Oncol,1996, 172(1):81-90.
[9]	Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage ⅢA/ⅢB non-small cell lung cancer:Technical issues and results of a phase Ⅰ/Ⅱ trial. Int J Radiat Oncol Biol Phys, 2002, 54(2):348-356.
[10]	Lee SW, Choi EK, Lee J, et al. Phase Ⅱ study of three-dimensional conformal radiotherapy and concurrent mitomycin-c vinblastine andcisplatin chemotherapy for stage Ⅲ locally advanced,unresectablen on-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2003, 56(4):996-1004.

[1]	姜炜 , 郭阳 , 徐玲 , 赵卫生 . 立体定向放射治疗胰腺癌. 国际放射医学核医学杂志, 2007, 31(1): 55-57.
[2]	杜芳芳 , 王政 , 姜炜 . 老年胶质母细胞瘤的治疗进展. 国际放射医学核医学杂志, 2019, 43(5): 479-483. doi: 10.3760/cma.j.issn.1673-4114.2019.05.017
[3]	郭树龙 , 张久君 . 相对低剂量甲泼尼龙联合⁹⁹Tc-MDP治疗老年Graves眼病的疗效观察. 国际放射医学核医学杂志, 2009, 33(5): 287-290. doi: 10.3760/cnla.j.issn.1673-4114.2009.05.010
[4]	李小东 , 郭永涛 , 赵洪刚 , 张遵城 , 董华 , 冯仲苏 , 柴树德 , 郑广钧 . CT引导¹²⁵I粒子植入治疗晚期非小细胞肺癌的应用. 国际放射医学核医学杂志, 2007, 31(6): 377-380.
[5]	付丽 , 张遵城 , 于兆晨 , 郑广钧 , 田美荣 . CT引导¹²⁵I粒子治疗非小细胞肺癌的辐射防护护理干预. 国际放射医学核医学杂志, 2009, 33(5): 312-315. doi: 10.3760/cnla.j.issn.1673-4114.2009.05.018
[6]	鲁杰 , 刘强 . 老年鼻咽癌115例放疗疗效评价. 国际放射医学核医学杂志, 2008, 32(4): 254-255.
[7]	田素青 . 放射性粒子永久植入治疗非小细胞肺癌的研究. 国际放射医学核医学杂志, 2007, 31(3): 188-191.
[8]	汪俊剑 , 黄少祥 . 化疗和放化疗同步治疗局部晚期非小细胞肺癌临床观察. 国际放射医学核医学杂志, 2008, 32(5): 317-319.
[9]	郑海燕 . 放疗联合顺铂和多西他赛治疗非小细胞肺癌的临床观察. 国际放射医学核医学杂志, 2009, 33(5): 319-320. doi: 10.3760/cnla.j.issn.1673-4114.2009.05.020
[10]	秦文琼 , 高硕 . PET/CT与临床预后因素在弥漫大B细胞淋巴瘤疗效评价及预后评估中的应用. 国际放射医学核医学杂志, 2017, 41(6): 437-442. doi: 10.3760/cma.j.issn.1673-4114.2017.06.010

点击查看大图

计量

文章访问数: 1417
HTML全文浏览量: 86
PDF下载量: 2

常规放疗结合后程立体定向放射治疗老年非小细胞肺癌患者的预后分析

1. 300060 天津, 天津市环湖医院放疗科;
2. 300052 天津, 天津医科大学总医院放疗科

收稿日期: 2006-08-14

关键词:

摘要: 目的观察老年非小细胞肺癌立体定向放疗疗效,并探讨其预后因子。方法 128例老年非小细胞肺癌患者行常规放疗结合立体定向放疗,定期随访。结果全组患者1年生存率65.72%,单因素分析表明肿瘤体积、肿瘤剂量、卡氏评分影响近期结果,多因素分析仅肿瘤体积和肿瘤剂量为近期疗效预后因子,与生存期有关的预后因素为近期疗效、肿瘤剂量、临床分期。结论立体定向放疗可延长生存时间,对Ⅲ期患者,肿瘤剂量提高至72Gy是安全的。